Featuring an interview with Dr Rana R McKay, including the following topics:
- Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
- Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
- Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)
- Takeaways from the Phase III EMBARK study (19:36)
- Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)
- Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)